FDA expands essential thrombocythemia care - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA expands essential thrombocythemia care

Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.

  • By

  • Kathryn Wighton

  • September 1, 2026

  • 2 min

Share

Clinical Scorecard: FDA expands essential thrombocythemia care

At a Glance

CategoryDetail
ConditionEssential Thrombocythemia
Key MechanismsOverproduction of platelets in the bone marrow
Target PopulationAdults with essential thrombocythemia, including newly diagnosed patients
Care SettingOncology and hematology clinics

Key Highlights

  • FDA approved ropeginterferon alfa-2b-njft for essential thrombocythemia treatment
  • First new treatment for ET in nearly 30 years
  • Higher durable response rates compared to anagrelide
  • Treatment reduces thromboembolic events over 12 months
  • Boxed warning for potential severe side effects

Guideline-Based Recommendations

Diagnosis

  • Diagnosis based on clinical criteria and laboratory findings

Management

  • Ropeginterferon alfa-2b-njft as a treatment option for ET

Monitoring & Follow-up

  • Monitor for neuropsychiatric, autoimmune, ischemic, and infectious disorders

Risks

  • Increased risk of blood clots, abnormal bleeding, and complications such as heart attack and stroke

Patient & Prescribing Data

Adults with essential thrombocythemia

Ropeginterferon alfa-2b-njft targets disease-driving bone marrow cells

Clinical Best Practices

  • Consider patient history for contraindications before prescribing
  • Monitor platelet counts and overall disease burden during treatment

Related Resources & Content

Original Source(s)

FDA expands essential thrombocythemia care

  • by Kathryn Wighton

  • September 1, 2026

Related Content

Social vulnerability may contribute to disparities in ovarian cancer survival

Neighborhood vulnerability was associated with poorer survival among women with epithelial ovarian cancer, with a stronger association among Black women.

Study uncovers factors potentially associated with lower LUTS risk

Sexual frequency was associated with lower odds of urinary symptoms in a US cohort but not a Chinese cohort.

High progesterone may be tied to syringoma

Elevated levels occurred in 29% of women with the condition compared with 6% of controls in a cross-sectional study.